Do new diabetes drugs show pancreatitis signals in FAERS?
FAERS 2019–2021 reports link pancreatitis strongly to DPP-4 inhibitors and GLP-1 RAs, with liraglutide leading within GLP-1s.
Source
Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
Study at a glance
- Design
- Qualitative / archival — FAERS spontaneous adverse-event disproportionality analysis (ROR, PRR, EBGM, IC) for pancreatitis with GLP-1 RA, DPP-4, and SGLT2 drugs, 2019–2021
- N
- N=2313 · 2,313 pancreatitis reports linked to hypoglycemic agents in FAERS
- Population
- Spontaneous FAERS pancreatitis reports involving GLP-1 RAs, DPP-4 inhibitors, or SGLT2 inhibitors
- Outcome
- Disproportionality signals (ROR/PRR/EBGM/IC) for pancreatitis by drug class and agent
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Researchers mined FAERS (2019–2021) for pancreatitis with GLP-1 RAs, DPP-4 inhibitors, and SGLT2 inhibitors, requiring concurrence of ROR, PRR, EBGM, and IC for a signal.
What they found
Of 2,313 reports, 70.2% involved GLP-1 RAs; DPP-4 ROR 13.2 and GLP-1 ROR 9.65 were elevated; liraglutide had the highest GLP-1 association (ROR 6.83); ~17.7% of reports were serious.
The limits
What it doesn't show
Not incidence rates or proven causation—spontaneous reporting cannot adjust fully for indication, comorbidity, or reporting bias.
Key terms
- FAERS
- FDA Adverse Event Reporting System of spontaneous safety reports.
- ROR
- Reporting odds ratio; a disproportionality metric for drug–event pairs.
- GLP-1 RA
- Glucagon-like peptide-1 receptor agonist used in T2DM/weight management.
- DPP-4 inhibitor
- Dipeptidyl peptidase-4 inhibitor that prolongs endogenous incretin activity.
- SGLT2 inhibitor
- Sodium-glucose cotransporter-2 inhibitor promoting urinary glucose excretion.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
What study design best matches this paper?
Common questions
Which class had more raw reports?
GLP-1 RAs (~70% of the pancreatitis reports analyzed).
Which class had higher ROR?
DPP-4 inhibitors (13.2) vs GLP-1 (9.65) in their analysis.
Does this mean stop all GLP-1s?
No—signals warrant awareness and clinical judgment, not automatic discontinuation for every patient.
What defines a signal here?
Meeting thresholds on all four indices: ROR, PRR, EBGM, and IC.
More on Diabetes